Accordingly, a previous NMA and systematic review comparing different ICIs safety in NSCLC and melanoma treatment, already pointed towards a lower risk of any or high-grade AEs for atezolizumab as compared to durvalumab and the PD-1 inhibitor nivolumab [51]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.